Who are Zolendronic Acid's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Boniva, Zometa, Fosamax, Aredia, raloxifene HCI and alendronate Na, ZA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/zolendronic-acid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Zolendronic Acid — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Zolendronic Acid (Zolendronic Acid) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bisphosphonate. Area: Oncology, Bone Metabolism.

marketed Bisphosphonate Farnesyl pyrophosphate synthase Oncology, Bone Metabolism Small molecule Live · refreshed every 30 min

Target snapshot

Zolendronic Acid (Zolendronic Acid) — Wales Cancer Trials Unit. Zoledronic acid inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Zolendronic Acid TARGET	Zolendronic Acid	Wales Cancer Trials Unit	marketed	Bisphosphonate	Farnesyl pyrophosphate synthase
Boniva	IBANDRONIC ACID	Hoffmann La Roche	marketed	Bisphosphonate	Farnesyl pyrophosphate synthase	2003-01-01
Zometa	ZOLEDRONIC ACID	Novartis	marketed	zoledronic acid	Farnesyl pyrophosphate synthase	2001-01-01
Fosamax	ALENDRONIC ACID	Merck And Co Inc	marketed	Vitamin D [EPC]	Farnesyl pyrophosphate synthase	1995-01-01
Aredia	PAMIDRONIC ACID		marketed	Bisphosphonate	Farnesyl pyrophosphate synthase	1991-01-01
raloxifene HCI and alendronate Na	raloxifene HCI and alendronate Na	Eli Lilly and Company	marketed	Selective estrogen receptor modulator (SERM) + bisphosphonate combination	Estrogen receptor (raloxifene); osteoclast farnesyl pyrophosphate synthase (alendronate)
ZA	ZA	Merck Sharp & Dohme LLC	marketed	Bisphosphonate	Farnesyl pyrophosphate synthase (indirect); hydroxyapatite in bone (binding site)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2031-12-05 — Fosamax · 9592195 · US

Sponsor landscape (Bisphosphonate class)

· 2 drugs in this class
Amgen · 2 drugs in this class
National Taiwan University Hospital · 2 drugs in this class
Sanofi · 2 drugs in this class
Ludwig-Maximilians - University of Munich · 2 drugs in this class
Chinese University of Hong Kong · 1 drug in this class
Chinese Society of Lung Cancer · 1 drug in this class
Aarhus University Hospital · 1 drug in this class
Eisai Inc. · 1 drug in this class
Daiichi Sankyo Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Zolendronic Acid — Competitive Intelligence Brief. https://druglandscape.com/ci/zolendronic-acid. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing